223 related articles for article (PubMed ID: 3945167)
1. MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice.
Fuller RW; Wong CJ; Hemrick-Luecke SK
Life Sci; 1986 Feb; 38(5):409-12. PubMed ID: 3945167
[TBL] [Abstract][Full Text] [Related]
2. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Fuller RW; Hemrick-Luecke SK
Life Sci; 1985 Sep; 37(12):1089-96. PubMed ID: 3875779
[TBL] [Abstract][Full Text] [Related]
3. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
[TBL] [Abstract][Full Text] [Related]
4. Enhanced selectivity of pargyline as an inhibitor of type B monoamine oxidase in harmaline-treated rats.
Fuller RW; Hemrick SK
Life Sci; 1978 Mar; 22(12):1083-6. PubMed ID: 642716
[No Abstract] [Full Text] [Related]
5. N-[2-(o-iodophenoxy)ethyl]cyclopropylamine hydrochloride (LY121768), a potent and selective irreversible inhibitor of type A monoamine oxidase.
Fuller RW; Hemrick-Luecke SK; Molloy BB
Biochem Pharmacol; 1983 Apr; 32(7):1243-9. PubMed ID: 6847714
[TBL] [Abstract][Full Text] [Related]
6. [Studies on monoamine oxidase. (Report 37) Effects of oxygen concentration on rat liver and brain monoamine oxidase (author's transl)].
Nakagawa K
Nihon Yakurigaku Zasshi; 1977 Apr; 73(3):297-305. PubMed ID: 21126
[TBL] [Abstract][Full Text] [Related]
7. Depletion of epinephrine in rat hypothalamus by Ro 4-1284: influence of pargyline and harmaline.
Fuller RW; Hemrick-Luecke SK
Brain Res Bull; 1980; 5(5):589-91. PubMed ID: 6903452
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of dehydropirlindole and other compounds on rat brain monoamine oxidase type A.
Gerardy J; Dresse A
Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):75-9. PubMed ID: 11853123
[TBL] [Abstract][Full Text] [Related]
9. Influence of harmaline on the ability of pargyline to alter catecholamine metabolism in rats.
Fuller RW; Hemrick-Luecke SK; Perry KW
Biochem Pharmacol; 1981 Jun; 30(11):1295-8. PubMed ID: 7271828
[No Abstract] [Full Text] [Related]
10. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
[TBL] [Abstract][Full Text] [Related]
11. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
[TBL] [Abstract][Full Text] [Related]
13. Elevation of epinephrine concentration in rat brain by LY51641, a selective inhibitor of type A monoamine oxidase.
Fuller RW; Hemrick-Luecke SK
Res Commun Chem Pathol Pharmacol; 1981 May; 32(2):207-21. PubMed ID: 7244360
[TBL] [Abstract][Full Text] [Related]
14. Biochemistry and physiology of monoamine oxidase (MAO) activity in the ring dove (Streptopelia risoria). I. Characteristics of MAO activity in vitro.
Hall TR; Lea RW; Vowles DM; Harvey S
Comp Biochem Physiol C Comp Pharmacol Toxicol; 1985; 82(2):417-22. PubMed ID: 2866915
[TBL] [Abstract][Full Text] [Related]
15. Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase.
Fowler CJ; Strolin Benedetti M
J Neurochem; 1983 Feb; 40(2):510-3. PubMed ID: 6822834
[TBL] [Abstract][Full Text] [Related]
16. Studies of monoamine oxidase and semicarbazide-sensitive amine oxidase. I. Inhibition by a selective monoamine oxidase-B inhibitor, MD 780236.
Kinemuchi H; Morikawa F; Ueda T; Arai Y
Jpn J Pharmacol; 1986 Jun; 41(2):183-9. PubMed ID: 3747265
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced changes in motor activity after selective MAO inhibition.
Gianutsos G; Carlson GM; Godfrey JG
Pharmacol Biochem Behav; 1983 Aug; 19(2):263-8. PubMed ID: 6634874
[TBL] [Abstract][Full Text] [Related]
18. The metabolism of dopamine by both forms of monoamine oxidase in the rat brain and its inhibition by cimoxatone.
Fowler CJ; Benedetti MS
J Neurochem; 1983 Jun; 40(6):1534-41. PubMed ID: 6406646
[TBL] [Abstract][Full Text] [Related]
19. Different sensitivity of mitochondrial and cytosolic monoamine oxidases to in vivo but not in vitro inhibition by specific irreversible inhibitors.
Moskvitina TA; Medvedev AE
Med Sci Monit; 2001; 7(1):17-9. PubMed ID: 11208486
[TBL] [Abstract][Full Text] [Related]
20. Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis.
Wang J; Edmondson DE
Biochemistry; 2011 Apr; 50(13):2499-505. PubMed ID: 21341713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
